ended6월 9일· 1 sources
OpenAI Eyes $1 Trillion Valuation as Age-Reversal Science Goes Human
1조 달러 몸값 OpenAI 상장 추진과 '회춘 약물' 임상 시험의 서막
Why it matters
OpenAI's confidential IPO filing signals a massive test for the AI market's $1 trillion ambitions, while David Sinclair's human trials for rejuvenation drugs mark a bold leap in longevity science. These developments, alongside Apple's Siri AI overhaul, highlight a technological era where AI and bio-reprogramming are no longer speculative but imminent.
1
Sources
+0
24h
—
Growth
103d
Active
OpenAI IPODavid SinclairRejuvenation DrugsSiri AIXPrizeChemical Reprogramming